科金特生物科技
COGT
29.52
+0.01
+0.03%
科金特生物科技
US · COGT
#2052 按市值排名
上市于 2016
29.52
+0.01
+0.03%
实时 - 追踪5344个代码 - 心跳于19秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了1家。
- 机构持股总比例下降了2.1个百分点。
机构持股
- 机构持股比例
- 117.19% -2.12pp
- 机构数量
- 389 -1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund75.22%
Hedge Fund29.14%
VC/PE Fund8.20%
Public Company3.01%
Private Company0.57%
Individual/Insider0.56%
Government Pension Fund0.45%
Sovereign Wealth Fund0.31%
Insurance Company0.28%
主要股东 截至 2026-06-30
FMR
14.80% · 25.68M 股
BlackRock
10.00% · 17.35M 股
Vanguard Capital Management, LLC
4.97% · 8.63M 股
Vanguard Portfolio Management, LLC
4.65% · 8.07M 股
State Street Global Advisors
4.01% · 6.96M 股
Janus Henderson Group plc
3.82% · 6.62M 股
Fairmount Funds Management LLC
3.19% · 5.54M 股
Commodore Capital LP
3.11% · 5.40M 股
Point72 Asset Management, L.P.
3.03% · 5.26M 股
Deerfield Management Company, L.P.
2.88% · 5.01M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 36次买入 · 14次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Andrew Robbins | Chief Executive Officer | 0.27% |
| Cole Pinnow | Chief Commercial Officer | 0.10% |
| John Robinson | Chief Scientific Officer | 0.05% |
| Jessica Sachs | Chief Medical Officer | 0.05% |
| John Green | Chief Financial Officer | 0.05% |
| Evan Kearns | Chief Legal Officer | 0.04% |
| Arlene Morris | Independent Director | -- |
| Matthew Ros | Independent Director | -- |
| Todd Shegog | Independent Director | -- |
| Karen Jean Ferrante | Independent Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-30 | Karen Jean Ferrante | Independent Director | Other Derivative Acquisition | +759 | $31.59 |
| 2026-08-26 | Arlene Morris | Independent Director | Derivative Exercise and Sale | -45,510 | $2.52–37.54 |
| 2026-06-30 | Karen Jean Ferrante | Independent Director | Other Derivative Acquisition | +627 | $38.48 |
| 2026-06-08 | Arlene Morris | Independent Director | Other Derivative Acquisition | +17,901 | $31.98 |
| 2026-06-08 | Matthew Ros | Independent Director | Other Derivative Acquisition | +17,901 | $31.98 |
| 2026-06-08 | Todd Shegog | Independent Director | Other Derivative Acquisition | +17,901 | $31.98 |
| 2026-06-08 | Karen Jean Ferrante | Independent Director | Other Derivative Acquisition | +17,901 | $31.98 |
| 2026-06-08 | Christopher Cain | Independent Director | Other Derivative Acquisition | +17,901 | $31.98 |
| 2026-06-08 | Peter Harwin | Independent Chairperson | Other Derivative Acquisition | +17,901 | $31.98 |
| 2026-05-18 | Andrew Robbins | Chief Executive Officer | Other Acquisition | +160,000 | -- |
| 2026-05-18 | Andrew Robbins | Chief Executive Officer | Other Disposition | -160,000 | -- |
| 2026-03-31 | Karen Jean Ferrante | Independent Director | Other Derivative Acquisition | +686 | $35.24 |
| 2026-03-30 | Fairmount Funds Management LLC | -- | Derivative Exercise and Sale | -7,000,000 | $34.66 |
| 2026-01-21 | Fairmount Funds Management LLC | -- | Private Disposition | -3,500,000 | $36.40 |
| 2025-12-31 | Karen Jean Ferrante | Independent Director | Other Derivative Acquisition | +643 | $34.74 |
| 2025-12-25 | John Green | Chief Financial Officer | Open Market Disposition | -77,000 | $38.68 |
| 2025-12-25 | Evan Kearns | Chief Legal Officer | Open Market Disposition | -65,000 | $38.70 |
| 2025-12-25 | Jessica Sachs | Chief Medical Officer | Open Market Disposition | -82,642 | $38.70 |
| 2025-12-25 | John Robinson | Chief Scientific Officer | Open Market Disposition | -90,000 | $38.74 |
| 2025-12-16 | Andrew Robbins | Chief Executive Officer | Sale to Issuer | -367,497 | $39.45 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
科金特生物科技 讨论区 0 条评论